Abbott Laboratories (ABT) — Company Research

Last Updated: 3 August 2026

Abbott Laboratories is one of the few genuinely diversified healthcare companies left. Where most of its peers have narrowed down to a single specialism, Abbott still runs four separate businesses under one roof — medical devices, diagnostics, nutrition and branded generic medicines — and in March 2026 it added a fifth growth engine by buying Exact Sciences for roughly $21bn. This report walks through what Abbott actually sells, what the numbers say, and what has to go right or wrong from here. It uses only company filings, press releases and published market data. There are no analyst ratings or price targets anywhere in it.

1. Company Snapshot

Field	Value
Company	Abbott Laboratories
Ticker / Exchange	ABT / New York Stock Exchange
Sector	Healthcare — medical devices, diagnostics, nutrition, established pharmaceuticals
Founded	1888, Chicago, Illinois
Headquarters	Abbott Park, Illinois, United States
CEO / Leadership	Robert B. Ford — Chairman and Chief Executive Officer (CEO since March 2020, Chairman since December 2021)
Employees	Approximately 115,000 (FY2025 results release)
Fiscal year end	31 December
Share price	$105.70 (close, 31 July 2026)
Market cap	Approximately $184.1bn (1,741.8m shares outstanding × $105.70)
Revenue (FY2025)	$44,328m
Net income (FY2025, GAAP)	$6,524m
Adjusted diluted EPS (FY2025)	$5.15
Dividend	$0.63 per share per quarter ($2.52 annualised); 54 consecutive years of increases
R&D spend (FY2025)	$2,942m, or 6.6% of sales

2. Bull and Bear Case

Bull Case

• Four independent revenue engines: Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals each generated between $5.5bn and $21.4bn in FY2025, which means no single product cycle or reimbursement decision determines the whole company's year.
• Libre is a consumable, not a one-off sale: continuous glucose monitoring sales reached $2.0bn in the fourth quarter of 2025 alone, up 15% reported, and the business model depends on patients replacing sensors every 10 to 14 days rather than on winning a new capital sale each time.
• Electrophysiology has a new engine: the Volt pulsed field ablation system was approved by the FDA on 22 December 2025, giving Abbott a US entry into the fastest-growing category in cardiac ablation, and electrophysiology grew at a low-teens rate in the second quarter of 2026.
• Exact Sciences adds a whole oncology-diagnostics vertical: the deal closed on 23 March 2026 and brings Cologuard, Oncotype Dx and the Cancerguard multi-cancer screening programme into a diagnostics business that badly needed a growth offset to China pricing.
• Cash generation supports the dividend record: FY2025 operating cash flow was $9,566m against capital expenditure of $2,171m, leaving roughly $7.4bn of free cash flow to fund a payout that has now risen for 54 consecutive years.

Bear Case

• The infant-formula litigation has not gone away: a Missouri verdict of $495m has been upheld on appeal, an Illinois jury returned a further $53m compensatory and $17m punitive award in April 2026, and more than 800 federal necrotising enterocolitis cases remain outstanding.
• China diagnostics looks structurally reset, not cyclical: volume-based procurement cost the Diagnostics segment roughly $700m of FY2025 sales, and management's own framing has been that the China business stabilises rather than returns to growth.
• The Exact Sciences deal was funded with debt and dilutes near-term earnings: Abbott raised roughly $20bn of senior notes in March 2026 and cut its own FY2026 adjusted EPS guidance by about $0.20 to absorb the acquisition before later raising it back.
• Reported earnings look far worse than adjusted earnings: FY2025 GAAP diluted EPS of $3.72 sat 28% below the adjusted figure of $5.15, largely because of $1,682m of intangible amortisation, and the Exact Sciences purchase accounting widens that gap further from 2026.
• CGM is no longer an uncontested market: Dexcom grew FY2025 revenue 16% to $4.66bn and continues to compete directly in Abbott's fastest-growing device category, where reimbursement and pricing pressure tend to arrive together.

3. Business Segments

Abbott reports four segments. The figures below are FY2025 sales as disclosed in the fourth-quarter and full-year 2025 results release.

Segment	% of revenue	What it is
Medical Devices — $21,387m	48.2%	Diabetes Care (FreeStyle Libre CGM, $7,998m), Vascular ($2,995m), Electrophysiology ($2,764m), Rhythm Management ($2,649m), Structural Heart ($2,523m), Heart Failure ($1,448m) and Neuromodulation ($1,010m)
Diagnostics — $8,937m	20.2%	Core laboratory analysers and reagents, molecular, point of care and rapid diagnostics; now also the Exact Sciences oncology-screening portfolio from March 2026
Nutrition — $8,451m	19.1%	Paediatric nutrition (Similac) and adult nutrition (Ensure, Glucerna)
Established Pharmaceuticals — $5,536m	12.5%	Branded generic medicines sold exclusively in international and emerging markets; no US sales
Other / unallocated — $17m	0.0%	Residual items not allocated to a reportable segment

4. Business Model and Moat

How it makes money. Abbott sells physical product, not services or licences, and the majority of it is consumed and repurchased. A FreeStyle Libre sensor lasts 10 to 14 days. A core-laboratory analyser placed in a hospital pulls Abbott reagents behind it for the life of the instrument. An implanted device carries leads, programmers and eventual replacement. That structure is why revenue held up at $40.1bn even in 2023, the year COVID testing revenue collapsed.

Where the barrier to entry sits. The moat is regulatory and procedural rather than technological. A Class III device such as Volt or Navitor requires an FDA premarket approval supported by a full clinical trial, which takes years and tens of millions of dollars before a single unit is sold. Once approved, the second barrier is human: electrophysiologists and interventional cardiologists train on a specific platform and are slow to switch. Abbott obtained CE Mark for Volt in March 2025 and FDA approval in December 2025 — a nine-month gap that illustrates how the same product has to clear each jurisdiction separately.

Why the diversification matters commercially. Because four segments sell into overlapping customers — hospitals, labs, pharmacies, retailers — Abbott can fund a launch in one area from the cash flow of another. Established Pharmaceuticals, a low-glamour branded-generics business in emerging markets, throws off cash that helps pay for structural-heart trials. An AA-/Aa3 credit standing then lets the company raise $20bn of notes at short notice, which is what made the Exact Sciences purchase possible.

Scale and reach. Roughly 115,000 employees selling in more than 160 countries gives Abbott the distribution footprint to take a product global quickly once it is approved, and more than 60% of revenue is generated outside the United States.

5. Financial Health

All figures below are taken from Abbott's quarterly and annual results releases and from its filed financial statements. Long-term debt is the non-current balance-sheet figure at each fiscal year end.

Fiscal Year	Revenue ($m)	YoY %	GAAP EPS	Adjusted EPS	Dividend/share	Long-term debt (YE)
2021	43,075	+24.5%	$3.94	$5.21	$1.82	$17,296m
2022	43,653	+1.3%	$3.91	$5.34	$1.92	$14,522m
2023	40,109	−8.1%	$3.26	$4.44	$2.08	$13,599m
2024	41,950	+4.6%	$7.64 †	$4.67	$2.24	$12,625m
2025	44,328	+5.7%	$3.72	$5.15	$2.40	$9,896m

† FY2024 GAAP diluted EPS of $7.64 includes a non-cash tax valuation-allowance benefit of roughly $7.5bn. It is not comparable with the other years on a GAAP basis; the adjusted column is the like-for-like series.

The shape of the five years is worth reading carefully. The 2021 spike and the 2023 decline are both COVID testing artefacts — rapid diagnostics inflated 2021 and 2022, then fell away. Stripping that out, the underlying business has compounded in the mid single digits and long-term debt has been reduced every single year, from $17.3bn at the end of 2021 to $9.9bn at the end of 2025. That deleveraging is precisely what created the balance-sheet room to fund Exact Sciences in March 2026.

Quarter / Half	Revenue ($m)	Adjusted EPS	GAAP EPS
Q2 2026	12,600	$1.31	$0.53
Q1 2026	11,160	$1.15	$0.61
Q4 2025	11,459	$1.50	$1.01
Q3 2025	11,369	$1.30	$0.94
Q2 2025	11,142	$1.26	$1.01
Q1 2025	10,358	$1.09	$0.76
FY2025 total	44,328	$5.15	$3.72

Second-quarter 2026 sales of $12.6bn were up 13.0% on a reported basis but only 4.8% on a comparable basis — the gap is Exact Sciences, whose first full quarter of oncology-diagnostics revenue is inside the reported number. The GAAP line tells the other half of the story: GAAP EPS fell to $0.53 while adjusted EPS rose to $1.31, because acquisition accounting and intangible amortisation from the deal now sit in reported earnings.

6. Valuation Metrics

Raw metrics, August 2026. Not opinions on whether the stock is cheap or expensive.

Metric	Value
Market cap	~$184.1bn (1,741.8m shares outstanding × $105.70 close, 31 July 2026)
Enterprise value	~$188.1bn (market cap $184.1bn + total debt $12,929m − cash and short-term investments $8,939m, per the 31 December 2025 balance sheet: long-term debt $9,896m, current portion $3,033m, cash $8,522m, short-term investments $417m)
Trailing P/E (GAAP)	~34.2x ($105.70 / TTM GAAP diluted EPS $3.09, being Q3 2025 $0.94 + Q4 2025 $1.01 + Q1 2026 $0.61 + Q2 2026 $0.53). Distorted upward by Exact Sciences purchase accounting and intangible amortisation; on FY2025 GAAP EPS of $3.72 the multiple is ~28.4x
P/E (forward)	~19.1x ($105.70 / $5.525, the midpoint of Abbott's raised FY2026 adjusted diluted EPS guidance of $5.45–$5.60)
P/S (TTM)	~3.95x ($184.1bn / TTM revenue $46,588m, being the four quarters Q3 2025 through Q2 2026)
EV/EBITDA (TTM)	~16.8x (EV $188.1bn / FY2025 EBITDA $11,169m; EBITDA = operating income $8,053m + depreciation $1,434m + intangible amortisation $1,682m)
P/FCF	~24.9x (market cap $184.1bn / free cash flow $7,395m; FCF = operating cash flow $9,566m − capital expenditure $2,171m per the FY2025 cash flow statement)
52-week high	$137.49
52-week low	$81.97 (11 May 2026)
Short interest (% of float)	1.07% (18.49m shares short against a float of approximately 1,731.1m shares, latest reported settlement period)
Days to cover	~2.25 days (based on average daily volume of approximately 8.23m shares)
Dividend yield	~2.4% ($2.52 annualised / $105.70)

Two things stand out. The gap between the trailing GAAP multiple and the forward adjusted multiple is unusually wide right now, and almost all of it is acquisition accounting rather than operating deterioration. And the enterprise value sits only about $4bn above the market cap, because Abbott spent four years paying debt down before it spent $21bn on Exact Sciences — the balance-sheet effect of the March 2026 notes issuance will show up in the FY2026 year-end figures rather than in the FY2025 ones used above.

If you want to look at the price action alongside these numbers, the ChartsView Live Charts page carries the full interactive chart, and the Economic Calendar lists the macro releases that tend to move large-cap healthcare.

7. What Are They Building

Abbott spent $2,942m on research and development in FY2025, equal to 6.6% of sales. That budget is spread across all four segments rather than concentrated in one, which is why the pipeline reads as a list of separate races rather than a single bet.

• Dual glucose-ketone sensing. Abbott secured CE Mark on 27 May 2026 for the Libre Duo, described by the company as the world's first dual glucose-ketone sensor. European launches are planned for later in 2026. The US filing is outstanding, with approval expected in the second half of 2026.
• Consumer biowearables. Lingo and Libre Rio extend the Libre sensor platform beyond prescribed diabetes management into over-the-counter consumer metabolic tracking, opening a market that does not depend on reimbursement.
• Pulsed field ablation. Volt received FDA approval on 22 December 2025 on the strength of the VOLT-AF IDE trial, which reported 93.1% freedom from arrhythmia at six months in paroxysmal atrial fibrillation and 81.9% in persistent cases. Abbott followed with CE Mark for TactiFlex Duo, a catheter that can deliver both radiofrequency and pulsed field energy.
• Structural heart. TriClip for tricuspid repair and the Navitor transcatheter aortic valve both grew at double-digit rates in FY2025, and the Tendyne transcatheter mitral valve system was approved by the FDA in May 2025.
• Peripheral vascular. Esprit BTK, a resorbable scaffold for below-the-knee peripheral artery disease, carries CE Mark and addresses a condition that has historically had few durable device options.
• Oncology diagnostics. The integration of Exact Sciences brings Cologuard colorectal screening, Oncotype Dx recurrence testing, Oncodetect molecular residual disease testing and the Cancerguard multi-cancer early detection programme into Abbott's diagnostics business.

8. Competitive Landscape

Abbott does not have a single competitor that overlaps with all four of its segments. It meets Medtronic and Boston Scientific in cardiac rhythm and electrophysiology, Dexcom in glucose monitoring, Danaher and Becton Dickinson in diagnostics, and Johnson & Johnson across MedTech generally.

Peer	Market cap (August 2026)	Key 2025 metric
Johnson & Johnson (JNJ)	~$618bn (31 July 2026)	FY2025 total revenue of $94.2bn, up 6.0%, of which MedTech contributed $33.8bn
Danaher (DHR)	~$137bn (31 July 2026)	FY2025 revenue of $24.6bn, up 3.0%, with adjusted diluted EPS of $7.80
Stryker (SYK)	~$127bn (13 July 2026)	FY2025 revenue of approximately $25.1bn
Medtronic (MDT)	~$109bn (31 July 2026)	FY2026 revenue of $36.4bn to April 2026, up 8.4% reported, the strongest growth in ten years
Boston Scientific (BSX)	~$71bn (June 2026)	FY2025 net sales of approximately $20.1bn, up 19.9% reported, with adjusted EPS of $3.06
Becton Dickinson (BDX)	~$45bn (June 2026)	FY2025 revenue of $21.84bn for the year to September 2025, up 8.2%
Dexcom (DXCM)	~$29.6bn (17 July 2026)	FY2025 revenue of $4.662bn, up 16%, entirely in continuous glucose monitoring

Peer market capitalisations are drawn from different dates in June and July 2026 and should be treated as approximate rather than simultaneous snapshots.

9. Insider Activity

Chairman and Chief Executive Officer Robert B. Ford is the name to watch in Abbott's 2026 filings. He made an open-market purchase in January 2026 while the shares were falling toward what would become their 52-week low, which is a different signal from the routine tax-withholding dispositions that make up most executive Form 4 activity at a company of this size. Director John G. Stratton bought in May 2026, closer still to the low.

Name	Date	Type	Shares	Price	Value	Plan Type
Robert B. Ford (Chairman & CEO)	23 Jan 2026	Open-market purchase	18,800	$107.13	~$2,013,966	Discretionary purchase
Robert B. Ford (Chairman & CEO)	27 Feb 2026	Disposition	30,308	$116.26	~$3,523,607	Tax withholding on vesting
Mary K. Moreland (EVP)	27 Feb 2026	Disposition	4,630	$116.26	~$538,284	Tax withholding on vesting
Mary K. Moreland (EVP)	2 Mar 2026	Open-market sale	613	$115.58	~$70,851	Not specified in filing summary
John G. Stratton (Director)	7 May 2026	Open-market purchase	2,000	$86.82	~$173,640	Discretionary purchase

Values are calculated from the reported share counts and prices and are approximate. Readers should verify individual transactions directly against the Form 4 filings on SEC EDGAR before drawing conclusions.

10. Key Risks

• Preterm infant-formula litigation: a $495m Missouri verdict against Abbott has been upheld on appeal, an Illinois jury awarded a further $53m in compensatory and $17m in punitive damages in April 2026, and more than 800 federal necrotising enterocolitis cases remain active against Abbott and Mead Johnson. The tail risk here is not one verdict but the aggregate of many.
• China volume-based procurement: centralised tender pricing removed roughly $700m of Diagnostics sales in FY2025, and because Abbott held 40% to 45% share in some assay categories it absorbed the full price cut without a volume offset. Management's expectation has been stabilisation rather than recovery.
• Acquisition integration and leverage: Exact Sciences was bought for roughly $21bn and funded with about $20bn of new senior notes. It reduced FY2026 adjusted EPS guidance by around $0.20 on announcement. Integration slippage or slower-than-expected Cologuard and Cancerguard uptake would leave Abbott carrying the interest cost without the growth.
• Competitive pressure in continuous glucose monitoring: Libre is Abbott's single largest growth driver at $7,998m of FY2025 sales, and Dexcom grew 16% in the same year. Sustained competition in a reimbursed category usually shows up as price erosion before it shows up as share loss.
• Nutrition volumes and pricing: Nutrition sales fell 8.9% on a reported basis in the fourth quarter of 2025 on lower volumes and deliberate price actions. The recovery depends on 2026 product launches landing as planned.
• Currency and trade policy: more than 60% of Abbott's revenue is earned outside the United States, so dollar strength is a recurring drag on reported growth. Abbott has separately flagged tariff uncertainty and is investing to diversify its manufacturing footprint in response.
• Regulatory compliance cost: European Medical Device Regulation and In Vitro Diagnostic Regulation compliance appears as a recurring specified item in every quarterly non-GAAP reconciliation, and the underlying cost does not go away simply because it is excluded from adjusted earnings.

11. Recent Developments

• 12 Dec 2025 — Dividend raised for a 54th consecutive year. The board declared its 408th consecutive quarterly dividend and increased the rate to $0.63 per share, payable 13 February 2026.
• 22 Dec 2025 — FDA approves the Volt pulsed field ablation system. Approval gave Abbott its first US pulsed field ablation offering for atrial fibrillation, supported by VOLT-AF IDE trial results of 93.1% arrhythmia-free survival at six months in paroxysmal patients.
• 22 Jan 2026 — Fourth-quarter and full-year 2025 results. FY2025 sales of $44,328m, up 5.7%, GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, up 10%. Abbott issued initial FY2026 guidance of 6.5% to 7.5% comparable sales growth and $5.55 to $5.80 adjusted EPS.
• 23 Mar 2026 — Exact Sciences acquisition completed. Abbott closed the roughly $21bn purchase, funded through a $20bn senior notes offering completed earlier in March, adding Cologuard, Oncotype Dx, Oncodetect and Cancerguard to its diagnostics portfolio.
• 10 Apr 2026 — Illinois jury returns a further formula verdict. Four mothers were awarded $53m in compensatory and $17m in punitive damages in a state-court trial concerning Similac Special Care 24. Abbott has said it will appeal.
• 16 Apr 2026 — First-quarter 2026 results and guidance reset. Sales of $11,160m, GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15. Abbott lowered its FY2026 adjusted EPS range to $5.38 to $5.58 to absorb roughly $0.20 of Exact Sciences dilution.
• 27 May 2026 — CE Mark for dual glucose-ketone sensing. Abbott secured European approval for what it describes as the world's first dual glucose-ketone sensor, with launches planned in selected European markets later in 2026.
• 12 Jun 2026 — 410th consecutive quarterly dividend declared. The board declared $0.63 per share, payable 17 August 2026 to shareholders of record on 15 July 2026.
• 16 Jul 2026 — Second-quarter 2026 results and raised guidance. Sales of $12.6bn, up 13.0% reported and 4.8% comparable, with adjusted diluted EPS of $1.31 and GAAP diluted EPS of $0.53. Abbott raised its FY2026 adjusted EPS range to $5.45 to $5.60 and reaffirmed comparable sales growth guidance of 6.5% to 7.5%. Growth was led by low-teens electrophysiology and high-single-digit rhythm management, diabetes care and heart failure, plus the first full quarter of Exact Sciences revenue. Abbott returned $2.1bn to shareholders in the quarter.

12. Key Dates and Catalysts

• 17 Aug 2026 — payment date for the 410th consecutive quarterly dividend of $0.63 per share; record date was 15 July 2026
• Expected Oct 2026 — third-quarter 2026 results. Third-party earnings calendars indicate 21 October 2026, but this has not been confirmed on Abbott's own investor relations calendar at the time of writing
• Expected Dec 2026 — the board's customary December dividend declaration, which has carried an increase in each of the last 54 years
• Expected H2 2026 — FDA decision on the Libre Duo dual glucose-ketone sensor, already CE-marked in Europe since 27 May 2026
• Expected 2026 — further European market launches of Libre Duo following the May 2026 CE Mark
• TBD — appellate rulings and further state-court trial dates in the necrotising enterocolitis infant-formula litigation, where more than 800 federal cases remain outstanding

Abbott's fiscal year ends on 31 December, so the fourth-quarter and full-year 2026 results, together with initial FY2027 guidance, would normally follow in late January 2027. Readers tracking these dates alongside macro releases may find the ChartsView Economic Calendar useful, and discussion of individual names takes place on the ChartsView Forum.

---

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.